[Pancreatic enzyme substitution in patients with mucoviscidosis].
In CF-patients physical development is an important prognostic factor. Therefore, maldigestion in consequence of an exocrine pancreatic insufficiency must be payed special attention to. Only the acid-protected microsphere pancreatin preparations should be used for enzyme substitution. In estimating of effectiveness both subjective (pains, tolerance) and particularly objective parameters (balance investigations, stool-weight and -frequency, physical development) should be considered. Referring to this the determination of fecal chymotrypsin-concentration is unsuitable. There are further possibilities for increasing the enzyme efficiency, which could soon become applicable.
Henker
J
J
Klinik für Kinderheilkunde, Medizinischen Akademie Carl Gustav Carus Dresden, DDR.
D003550:Cystic Fibrosis / Q000628:therapy*; D010188:Exocrine Pancreatic Insufficiency / Q000628:therapy*; D006801:Humans; D010184:Pancreatic Extracts / Q000008:administration & dosage*; D010186:Pancreatic Function Tests; D010194:Pancreatin / Q000008:administration & dosage*
D010184:Pancreatic Extracts; D010194:Pancreatin
Pankreasenzymsubstitution bei Mukoviszidose-Patienten.